KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Assets Average: 2011-2025

Historic Assets Average for Sarepta Therapeutics (SRPT) over the last 13 years, with Sep 2025 value amounting to $3.6 billion.

  • Sarepta Therapeutics' Assets Average rose 2.12% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 2.12%. This contributed to the annual value of $3.6 billion for FY2024, which is 13.06% up from last year.
  • Sarepta Therapeutics' Assets Average amounted to $3.6 billion in Q3 2025, which was up 0.39% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Assets Average registered a high of $3.8 billion during Q4 2024, and its lowest value of $2.7 billion during Q3 2021.
  • Its 3-year average for Assets Average is $3.4 billion, with a median of $3.3 billion in 2024.
  • Over the last 5 years, Sarepta Therapeutics' Assets Average had its largest YoY gain of 20.54% in 2021, and its largest YoY loss of 5.25% in 2021.
  • Sarepta Therapeutics' Assets Average (Quarterly) stood at $2.9 billion in 2021, then grew by 8.16% to $3.1 billion in 2022, then grew by 1.43% to $3.2 billion in 2023, then increased by 18.65% to $3.8 billion in 2024, then increased by 2.12% to $3.6 billion in 2025.
  • Its Assets Average stands at $3.6 billion for Q3 2025, versus $3.6 billion for Q2 2025 and $3.7 billion for Q1 2025.